Loading…
Medtronic and Tandem Diabetes Care have entered into a non-exclusive patent cross-license agreement for diabetes technologies, covering existing and new products for at least five years, with no payments exchanged.
“Cross-licensing each other’s patent portfolios enables both companies to focus on helping people with diabetes through innovation of future products and services, while avoiding the distraction of potential legal disagreements.”news.medtronic.com
Summarized from public sources; check the original articles before acting on it.